Neutrophile-to-lymphocyte, lymphocyte-to-monocyte, and platelet-to-lymphocyte ratios as prognostic and response biomarkers for resectable locally advanced gastric cancer

Table 2 Relationship between neutrophil-to-lymphocyte, lymphocyte-to-monocyte, and platelet-to-lymphocyte ratios and clinicopathological variables in patients with resectable locally advanced gastroesophageal cancer

	NLR, mean ± SD	P value	LMR, mean ± SD	P value	PLR, mean ± SD	P value
Age		0.37		0.323		0.335
< 75 yr (n = 262)	4.72 ± 7.24		5.37 ± 9.66		178.88 ± 129.45
≥ 75 yr (n = 33)	4.21 ± 5.94		4.69 ± 4.06		214.98 ± 252.77
Sex		0.073		0.435		0.177
Male (n = 176)	4.19 ± 4.33		5.12 ± 4.9		169.61 ± 120.07
Female (n = 119)	5.37 ± 9.84		5.55 ± 13.24		202.6 ± 146.38
Treatment suspension due to toxicity		0.336		0.818		0.144
Yes (n = 22)	5.32 ± 5.5		5.05 ± 3.89		208.26 ± 136.91
No (n = 273)	4.61 ± 7.22		5.31 ± 9.5		180.87 ± 149.11
Systemic progression under preFLOT		0.935		0.287		0.022
Yes (n = 24)	4.66 ± 4.48		3.78 ± 2.9		251.94 ± 173.3
No (n = 271)	4.66 ± 7.29		5.43 ± 9.55		176.8 ± 144.54
T stage regression		0.743		0.021		0.62
Yes (n = 126)	4.14 ± 3.94		4.38 ± 3.64		168.23 ± 117.2
No (n = 138)	4.73 ± 8.97		6.5 ± 12.84		177.73 ± 145.62
N stage regression		0.119		0.635		0.157
Yes (n = 156)	5.04 ± 8.81		5.76 ± 12.04		184.45 ± 140.76
No (n = 115)	4.06 ± 4.56		4.91 ± 4.29		166.13 ± 150.31
Tumor downstaging		0.081		0.873		0.82
Yes (n = 161)	5.07 ± 8.58		4.7 ± 4.27		180.13 ± 139.93
No (n = 103)	4.02 ± 4.74		6.58 ± 14.42		197.79 ± 154.23
TRG		0.9		0.99		0.305
Partial/incomplete or complete regression (n = 161)	4.87 ± 8.45		5.17 ± 11.49		180.4 ± 139.45
No evidence of regression (n = 86)	4.77 ± 5.3		4.45 ± 3.63		189.73 ± 157.16
Pathological complete response		0.511		0.472		0.832
Yes (n = 48)	4.32 ± 3.73		4.62 ± 4.1		177 ± 138.81
No (n = 191)	5 ± 8.23		5.09 ± 10.54		183.87 ± 151.46
Mortality status at the end of study time		0.082		0.14		0.013
Alive (n = 233)	4.47 ± 7.45		5.6 ± 10.18		175.64 ± 149.02
Dead (n = 62)	5.38 ± 5.57		4.15 ± 3.45		210.27 ± 142.87

FLOT: Fluorouracil plus leucovorin, oxaliplatin, and docetaxel; LMR: Lymphocyte-to-monocyte ratio; NLR: Neutrophile-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; preFLOT: Preoperative fluorouracil plus leucovorin, oxaliplatin, and docetaxel; SD: Standard deviation; TRG: Tumor regression grade.